eXmoor pharma’s manufacturing facility receives licence from MHRA
The company’s Cell & Gene Therapy Centre can now offer a full range of GMP services
Read More
Tag: gene therapy
Coave Therapeutics and ABL link up to develop gene therapy manufacturing processes
Agreement between the two companies includes process development of AAV-based gene therapies
Read More
bluebird bio re-evaluates gene therapy strategy in ‘untenable’ European market
US biotech company says European payers have ‘not yet evolved their approach to gene therapy’
Read More
NICE ‘no’ for Orchard Therapeutics’ gene therapy Libmeldy
NICE concluded the cost-effectiveness estimates for Libmeldy are unlikely to be within the range that it would consider an effective use of NHS resources
Read More
bluebird bio’s sickle cell gene therapy granted MHRA ‘innovation passport’
Innovation passport designation scheme aims to reduce the time to market for promising treatments
Read More
Zolgensma shows promise in presymptomatic SMA patients
Children treated with gene therapy prior to symptom presentation achieved motor milestones not seen in the natural history of SMA
Read More
Biogen’s inherited eye disease gene therapy misses the mark in late-stage trial
Gene therapy was being evaluated for the treatment of the rare eye disease choroideremia
Read More
Vertex, CRISPR Therapeutics’ blood disorder gene therapy shows more promise
CTX001 is being evaluated as a one-time treatment for transfusion dependent beta thalassemia and sickle cell disease
Read More
Cell and Gene Therapy Catapult forms consortium of over 20 organisations
Consortium will assess multiple process analytical technologies used in the cell and gene therapy industry
Read More
Biogen partners with Ginkgo Bioworks on gene therapy manufacturing platform
Collaboration will aim to address challenge of timely and costly AAV-based vector manufacturing
Read More
Cross-industry alliance launches to increase awareness of cell and gene therapies in the UK
The Cell & Gene Collective is aiming to advocate for the adoption of next-generation medicine in the UK
Read More
Biogen’s inherited eye disease gene therapy misses primary endpoint
Company maintained, however, that the study showed ‘positive trends’ across a number of prespecified secondary endpoints
Read More
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
